Bio-IT World December 23, 2025
TRIANA will continue development of their molecular glue degrader to clinical proof; Medra’s Physical AI autonomously allows scientists to adapt workflows through natural-language instructions; PsiThera will advance their Tumor Necrosis Factor superfamily preclinical programs; and more.
$130M: Series B for First-in-Class AL Amyloidosis Program
Protego Biopharma announced the completion of an oversubscribed $130 million Series B financing. Proceeds will advance Protego’s lead candidate, PROT-001, into a pivotal clinical trial for AL amyloidosis, a rare and often fatal condition caused by protein misfolding that leads to organ damage, especially in the heart.
$120M: Series B for Molecular Glue Degrader
TRIANA has closed its oversubscribed $120 million Series B financing round. The...
Today's Sponsors
Today's Sponsor